Overview
Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
Status:
Unknown status
Unknown status
Trial end date:
2019-04-01
2019-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is to evaluate the efficacy and safety of orally administered SA001 compared to placebo in patients with Dry Eye Syndrome .Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samjin Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:- Age over 19.
- Must meet all criteria listed below at least in one eye.
1. Fluorescein corneal staining score ≥ 2
2. Schirmer test ≤ 10mm in 5 mins
3. Tear break-up time ≤ 10 secs
Exclusion Criteria:
- Ocular disorder that may confound interpretation of study results.
- Wearing contact lenses 72 hrs prior to screening visit and unwilling to avoid wearing
contact lenses for the duration of the study period.
- History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal
refractive surgery within 12 months prior to screening visit, and/or any other
intraocular surgery within 90 days prior to screening visit.
- Female currently pregnant, nursing, or planning a pregnancy; or woman who has a
positive pregnancy test.
- Participation in other studies within 30 days of screening visit.